Antitubercular Agents

"Antitubercular Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Drugs used in the treatment of tuberculosis. They are divided into two main classes: "first-line" agents, those with the greatest efficacy and acceptable degrees of toxicity used successfully in the great majority of cases; and "second-line" drugs used in drug-resistant cases or those in which some other patient-related condition has compromised the effectiveness of primary therapy.

Descriptor ID	D000995
MeSH Number(s)	D27.505.954.122.085.255
Concept/Terms	Antitubercular Agents Antitubercular Agents Agents, Antitubercular Antitubercular Drugs Drugs, Antitubercular Tuberculostatic Agents Agents, Tuberculostatic

Below are MeSH descriptors whose meaning is more general than "Antitubercular Agents".

Chemicals and Drugs [D]
Chemical Actions and Uses [D27]
Pharmacologic Actions [D27.505]
Therapeutic Uses [D27.505.954]
Anti-Infective Agents [D27.505.954.122]
Anti-Bacterial Agents [D27.505.954.122.085]
Antitubercular Agents [D27.505.954.122.085.255]

Below are MeSH descriptors whose meaning is related to "Antitubercular Agents".

Below are MeSH descriptors whose meaning is more specific than "Antitubercular Agents".

Antitubercular Agents
Antibiotics, Antitubercular

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Antitubercular Agents" by people in this website by year, and whether "Antitubercular Agents" was a major or minor topic of these publications.

Bar chart showing 55 publications over 25 distinct years, with a maximum of 8 publications in 2019

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1995	1	0	1
1999	0	1	1
2001	0	1	1
2003	0	1	1
2005	1	1	2
2006	3	0	3
2007	0	1	1
2008	1	0	1
2009	1	0	1
2010	1	0	1
2011	1	0	1
2012	1	2	3
2013	2	1	3
2014	0	1	1
2015	3	0	3
2016	3	1	4
2017	2	1	3
2018	1	1	2
2019	6	2	8
2020	2	1	3
2021	0	3	3
2022	1	1	2
2023	1	1	2
2024	3	0	3
2025	1	0	1

Below are the most recent publications written about "Antitubercular Agents" by people in Profiles.

Oluoch PO, Koh EI, Proulx MK, Reames CJ, Papavinasasundaram KG, Murphy KC, Zimmerman MD, Dartois V, Sassetti CM. Chemical genetic interactions elucidate pathways controlling tuberculosis antibiotic efficacy during infection. Proc Natl Acad Sci U S A. 2025 Mar 04; 122(9):e2417525122.

View in: PubMed
Zhao X, Di J, Luo D, Verma R, Verma SK, Verma S, Ravindar L, Koshle A, Dewangan HK, Gupta R, Chandra S, Deshpande S, Vaishnav Y, Rakesh KP. Thiazole - A promising scaffold for antituberculosis agents and structure-activity relationships studies. Bioorg Chem. 2025 Jan; 154:108035.

View in: PubMed
Prakash Babu S, Ezhumalai K, Raghupathy K, Karoly M, Chinnakali P, Gupte N, Paradkar M, Devarajan A, Dhanasekaran M, Thiruvengadam K, Dauphinais MR, Gupte AN, Shivakumar SB, Thangakunam B, Christopher DJ, Viswanathan V, Mave V, Gaikwad S, Kinikar A, Kornfeld H, Horsburgh CR, Chandrasekaran P, Hochberg NS, Salgame P, Gupta A, Roy G, Ellner J, Sinha P, Sarkar S. Factors Associated With Unfavorable Treatment Outcomes Among Persons With Pulmonary Tuberculosis: A Multicentric Prospective Cohort Study From India. Clin Infect Dis. 2024 Oct 15; 79(4):1034-1038.

View in: PubMed
Pandiarajan AN, Kumar NP, Selvaraj N, Ahamed SF, Viswanathan V, Thiruvengadam K, Hissar S, Shanmugam S, Bethunaickan R, Nott S, Kornfeld H, Babu S. Distinct TB-antigen stimulated cytokine profiles as predictive biomarkers for unfavorable treatment outcomes in pulmonary tuberculosis. Front Immunol. 2024; 15:1392256.

View in: PubMed
Viswanathan V, Devarajan A, Kumpatla S, Dhanasekaran M, Babu S, Kornfeld H. Effect of prediabetes on tuberculosis treatment outcomes: A study from South India. Diabetes Metab Syndr. 2023 Jul; 17(7):102801.

View in: PubMed
Kim S, Thal R, Szkwarko D. Management of Latent Tuberculosis Infection. JAMA. 2023 02 07; 329(5):421-422.

View in: PubMed
Vaz C, Jose NK, Tom JJ, Goodman GR, Lee JS, Padappayil RP, Madathil M, O'Cleirigh C, Rodrigues R, Chai PR. Formative acceptance of ingestible biosensors to measure adherence to TB medications. BMC Infect Dis. 2022 Sep 28; 22(1):754.

View in: PubMed
Koh EI, Oluoch PO, Ruecker N, Proulx MK, Soni V, Murphy KC, Papavinasasundaram K, Reames CJ, Trujillo C, Zaveri A, Zimmerman MD, Aslebagh R, Baker RE, Shaffer SA, Guinn KM, Fitzgerald M, Dartois V, Ehrt S, Hung DT, Ioerger TR, Rubin EJ, Rhee KY, Schnappinger D, Sassetti CM. Chemical-genetic interaction mapping links carbon metabolism and cell wall structure to tuberculosis drug efficacy. Proc Natl Acad Sci U S A. 2022 04 12; 119(15):e2201632119.

View in: PubMed
Kumar NP, Moideen K, Nancy A, Viswanathan V, Thiruvengadam K, Sivakumar S, Hissar S, Kornfeld H, Babu S. Acute Phase Proteins Are Baseline Predictors of Tuberculosis Treatment Failure. Front Immunol. 2021; 12:731878.

View in: PubMed
Amisi JA, Carter EJ, Masini E, Szkwarko D. Closing the loop in child TB contact management: completion of TB preventive therapy outcomes in western Kenya. BMJ Open. 2021 02 23; 11(2):e040993.

View in: PubMed

People

Explore

Similar Concepts

Top Journals